Success Metrics

Completion Rate
0%(0/2)
Active Trials
1(25%)
Terminated
2(50%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(3)

Detailed Status

Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated250%
withdrawn125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

NCT05693909
terminatedphase_1

Safety of SP-420 in the Treatment of Transfusional Iron Overload

NCT04741542
withdrawnphase_2

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

NCT03801889
terminatedphase_1

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

NCT02274233

Clinical Trials (4)

Showing 4 of 4 trials
NCT05693909Phase 2

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

Recruiting
NCT04741542Phase 1

Safety of SP-420 in the Treatment of Transfusional Iron Overload

Terminated
NCT03801889Phase 2

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Withdrawn
NCT02274233Phase 1

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4